Date: 2013-04-15
Type of information: Development agreement
Compound: danoprevir
Company: Roche (Switzerland) Ascletis (China)
Therapeutic area: Infectious diseases
Type agreement: development
commercialisation
Action mechanism: Danoprevir is an investigational protease inhibitor from Roche that is active against HCV genotypes 1 and 4.
Disease: chronic hepatitis C
Details: * On April 15, 2013, Roche and Ascletis have announced that they have entered into a collaboration to develop and commercialize Roche’s investigational drug danoprevir in China for the treatment of Hepatitis C Virus (HCV). Under the terms of the agreement, Ascletis will fund and be responsible for the development, regulatory affairs and manufacturing of danoprevir in greater China, including Taiwan, Hong Kong and Macau and receive payments upon reaching certain development and commercial milestones from Roche. Ascletis and Roche will collaborate for the clinical development and the commercialization. The contract also involves royalties.
Financial terms:
Latest news:
